aromatase inhibitor letrozole oncology
Selected indexed studies
- Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (Ann Oncol, 2024) [PMID:38729566]
- Ribociclib plus Endocrine Therapy in Early Breast Cancer. (N Engl J Med, 2024) [PMID:38507751]
- A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. (Ann Oncol, 2025) [PMID:39442617]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Letrozole: Pharmacology, toxicity and potential therapeutic effects. (2022) pubmed
- Letrozole. (2010) pubmed
- Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) pubmed
- Ribociclib plus Endocrine Therapy in Early Breast Cancer. (2024) pubmed
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. (2017) pubmed
- A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. (2025) pubmed
- Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial. (2025) pubmed
- Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. (2025) pubmed
- Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) pubmed
- Pivotal trials of letrozole: a new aromatase inhibitor. (1998) pubmed